Our Science

We invest in science to improve people’s health

We believe in the transformative impact of science to improve the quality of life of people living with chronic diseases. Scientific evidence is the way to create trust and reliability for patients, families and society as one. Our commitment is to dedicate the vast majority of resources towards research and innovation.

Our commitment is to dedicate the vast majority of resources towards research and innovation.

Pipeline

Our pipeline is powered by end-to-end research and development capabilities. The research team discovers promising new active pharmaceutical ingredients. From there, global development brings these investigational candidates through the full pre-clinical and clinical development process, including clinical trials designed to study safety and efficacy and lifecycle management.

Clinical trials

Advenion is committed to develop new therapies to treat selected chronic diseases in a sustainable way in a long and careful process. One of the most important steps in this process is the clinical trial where people volunteer to receive experimental therapy and be observed for its effects.

SCIENTIFIC
ADVISORY
BOARD

At Advenion we recognize that innovation comes from many sources. The constitution of the Advenion´s Scientific Advisory Board formalizes our belief in engaging top quality independent experts to help us design, manufacture, test, and promote the discovery and development processes. The Scientific Advisory Board provides external scientific review of our research and development activities and assists management in making in the process of scientific evaluation.

FERNANDO RODRÍGUEZ DE FONSECA
HEAD RESEARCHER IN NEUROPSYCHOPHARMACOLOGY

Fimabis

A recognized researcher and technologist in the area of Neuropsychopharmacology, Fernando has an extraordinary scientific career having published 283 scientific papers, directed 68 research projects and received 3 national research awards (including the Esteve Foundation International Research Award). He has registered 21 patents and has presented more than 150 international communications in conferences and congresses in the field of neuropsychopharmacology and medicinal chemistry.

His academic background includes a Post-Doctorate in Neuropsychopharmacology at the Scripps Research Institute (La Jolla, California, USA), a postdoctoral research at the University of California (UC at Irvine, USA), a PhD in Biochemistry and Molecular Biology from the Complutense University (Spain) and a degree in Medicine and Surgery from the Complutense University (Spain).

MARA DIERSSEN SOTOS
SENIOR SCIENTIST AT CENTRE FOR GENOMIC REGULATION (CRG)

IMIM Hospital del Mar Medical Research Institute

Dr Dierssen is the head of one of the groups of the Systems Biology program. The overall goal of Dr Dierssen research is to understand the role of putative candidate genes for human complex genetic diseases on brain cognitive systems, mainly using genetically modified mouse models. Overall, she has almost 180 publications, with major research papers in the upper 10% impact factor journals on her field, in international peer reviewed journals, 3 books and 22 book chapters. She has led research projects, funded by competitive calls under national and European schemes (FP7, Foundation Jerome Lejeune, Spanish R&D projects, Fundació La Marató, H2020, JPND etc), most of which as PI. Dr Dierssen is evaluator of different Scientific Committees and Boards such as National Evaluation Agency, Spanish Ministry of Education, ERC or Panel Expert for EU. She is past president of the International Behavioral and Neural Genetics Society, she has acted as executive committee member, vice-President and president of the Spanish Society of Neuroscience and has been founding member and president of the Trisomy 21 Research Society.

RAFAEL DE LA TORRE FORNELL
HEAD RESEARCHER IN NEURO-DEGENERATIVE DISEASES AND INTELLECTUAL DISABILITIES

IMIM Hospital del Mar Medical Research Institute

Dr. Rafael de la Torre, is the scientific-technological head of the Integrated Pharmacology and Neuroscience Systems (FINS) group at FIMIM. He directs a TECNIO center since 2006, being this the brand that identifies the technological centers experts in industrial research and technology transfer in Catalonia. This center, called BAPP (BioAnalysis, Proteomics and Pharmacology), promotes access to differential R&D capabilities, offers answers to the technological needs of the biopharmaceutical sector and promotes the international projection of companies in the same sector. TECNIO brings together the best technology centers and research centers of Catalan universities, as well as facilitates and promotes the establishment of public-private consortia to improve the transfer of knowledge from universities to companies.